Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.

NK cells adoptive cell therapy clinical trials cytokines expansion methods feeder cells innate immunity

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
05 Mar 2024
Historique:
received: 11 02 2024
revised: 01 03 2024
accepted: 01 03 2024
medline: 13 3 2024
pubmed: 13 3 2024
entrez: 13 3 2024
Statut: epublish

Résumé

Natural killer (NK) cells have gained attention as a promising adoptive cell therapy platform for their potential to improve cancer treatments. NK cells offer distinct advantages over T-cells, including major histocompatibility complex class I (MHC-I)-independent tumor recognition and low risk of toxicity, even in an allogeneic setting. Despite this tremendous potential, challenges persist, such as limited

Identifiants

DOI: 10.3390/cells13050451 PMID: 38474415
pubmed: 38474415
pii: cells13050451
doi: 10.3390/cells13050451
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fundação para a Ciência e Tecnologia
ID : SFRH/BD/144965/2019

Auteurs

Andreia Maia (A)

Molecular and Experimental Pathology Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
NK Cell Gene Manipulation and Therapy Laboratory, Division of Cellular Therapy and Stem Cell Transplant, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
NOVA Medical School, NOVA University of Lisbon, 1099-085 Lisbon, Portugal.
ORCID: 0000-0002-7860-6219

Mubin Tarannum (M)

NK Cell Gene Manipulation and Therapy Laboratory, Division of Cellular Therapy and Stem Cell Transplant, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Joana R Lérias (JR)

ImmunoTherapy/ImmunoSurgery, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
ORCID: 0000-0002-9874-5259

Sara Piccinelli (S)

NK Cell Gene Manipulation and Therapy Laboratory, Division of Cellular Therapy and Stem Cell Transplant, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Luis Miguel Borrego (LM)

Comprehensive Health Research Centre (CHRC), NOVA Medical School, Faculdade de Ciências Médicas (FCM), NOVA University of Lisbon, 1099-085 Lisbon, Portugal.
Immunoallergy Department, Hospital da Luz, 1600-209 Lisbon, Portugal.

Markus Maeurer (M)

ImmunoTherapy/ImmunoSurgery, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
I Medical Clinic, University of Mainz, 55131 Mainz, Germany.

Rizwan Romee (R)

NK Cell Gene Manipulation and Therapy Laboratory, Division of Cellular Therapy and Stem Cell Transplant, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Mireia Castillo-Martin (M)

Molecular and Experimental Pathology Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Pathology Service, Champalimaud Clinical Center, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
ORCID: 0000-0001-8926-6013

Classifications MeSH